Tounjian Advisory Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,042 shares of the biopharmaceutical company's stock, valued at approximately $662,000.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the company. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Finally, Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $836.48.
Get Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals stock traded up $5.42 during mid-day trading on Thursday, hitting $524.02. The company's stock had a trading volume of 540,327 shares, compared to its average volume of 871,847. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The stock's fifty day moving average price is $564.76 and its two-hundred day moving average price is $653.10. The stock has a market capitalization of $56.58 billion, a P/E ratio of 13.69, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $9.55 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
